Capricor Therapeutics (CAPR) Fundamentals 2026 — Revenue Analysis | SniperIQ
Capricor Therapeutics (CAPR) is a US-listed Healthcare company in Biotechnology with a market capitalization of $881M, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Capricor Therapeutics's market cap?
Capricor Therapeutics (CAPR) has a market capitalization of approximately $881M, trading at
What is Capricor Therapeutics's P/E ratio?
Capricor Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 4.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Capricor Therapeutics?
Capricor Therapeutics runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Capricor Therapeutics pay a dividend?
Capricor Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Capricor Therapeutics financially healthy?
Capricor Therapeutics carries a debt-to-equity ratio of 0.08x and a current ratio of 8.42x, with a market beta of 0.42. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Capricor Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Capricor Therapeutics (CAPR) the key facts are: market cap $881M, 52-week range 4.3-40.37. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Capricor Therapeutics's full fundamentals live
Get Capricor Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.